+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bladder Cancer Drugs Global Market Report 2020

  • ID: 4871547
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Alligator Bioscience AB
  • AndroScience Corp
  • Asana BioSciences LLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly
  • Johnson & Johnson
  • MORE
Bladder Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global bladder cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the bladder cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Bladder Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors
  • Companies Mentioned: Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alligator Bioscience AB
  • AndroScience Corp
  • Asana BioSciences LLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly
  • Johnson & Johnson
  • MORE
1. Executive Summary

2. Bladder Cancer Drugs Market Characteristics

3. Bladder Cancer Drugs Market Size And Growth
3.1. Global Bladder Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Bladder Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Bladder Cancer Drugs Market Segmentation
4.1. Global Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Non-Muscle-Invasive Bladder Cancer
  • Muscle-Invasive Bladder Cancer
4.2. Global Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Low-Grade Tumors
  • High-Grade Tumors
5. Bladder Cancer Drugs Market Regional And Country Analysis
5.1. Global Bladder Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Bladder Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Bladder Cancer Drugs Market
6.1. Asia-Pacific Bladder Cancer Drugs Market Overview
6.2. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Bladder Cancer Drugs Market
7.1. China Bladder Cancer Drugs Market Overview
7.2. China Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Bladder Cancer Drugs Market
8.1. India Bladder Cancer Drugs Market Overview
8.2. India Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Bladder Cancer Drugs Market
9.1. Japan Bladder Cancer Drugs Market Overview
9.2. Japan Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Bladder Cancer Drugs Market
10.1. Australia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Bladder Cancer Drugs Market
11.1. Indonesia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Bladder Cancer Drugs Market
12.1. South Korea Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Bladder Cancer Drugs Market
13.1. Western Europe Bladder Cancer Drugs Market Overview
13.2. Western Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Bladder Cancer Drugs Market
14.1. UK Bladder Cancer Drugs Market Overview
14.2. UK Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Bladder Cancer Drugs Market
15.1. Germany Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Bladder Cancer Drugs Market
16.4. France Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Bladder Cancer Drugs Market
17.1. Eastern Europe Bladder Cancer Drugs Market Overview
17.2. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Bladder Cancer Drugs Market
18.1. Russia Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Bladder Cancer Drugs Market
19.1. North America Bladder Cancer Drugs Market Overview
19.2. North America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Bladder Cancer Drugs Market
20.1. USA Bladder Cancer Drugs Market Overview
20.2. USA Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Bladder Cancer Drugs Market
21.1. South America Bladder Cancer Drugs Market Overview
21.2. South America Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Bladder Cancer Drugs Market
22.1. Brazil Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Bladder Cancer Drugs Market
23.1. Middle East Bladder Cancer Drugs Market Overview
23.2. Middle East Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Bladder Cancer Drugs Market
24.1. Africa Bladder Cancer Drugs Market Overview
24.2. Africa Bladder Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Bladder Cancer Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Bladder Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Bladder Cancer Drugs Market Competitive Landscape
25.2. Bladder Cancer Drugs Market Company Profiles
25.2.1. Pfizer
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Celgene Corporation
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Eli Lilly
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. AstraZeneca
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Bristol-Myers Squibb
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Bladder Cancer Drugs Market

27. Bladder Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Bladder Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alligator Bioscience AB
  • AndroScience Corp
  • Asana BioSciences LLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly
  • Johnson & Johnson
  • MORE
The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.

The global bladder cancer drugs market was valued at about $0.3 billion in 2018 and is expected to grow to $0.32 billion at a CAGR of 1.9% through 2022.

North America was the largest region in the bladder cancer drugs market in 2016, followed by Europe. This region is expected to remain the largest during the next five years. The bladder cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, the number of new bladder cancer cases increased by 20.3% in the USA and the number of new bladder cancer cases is estimated to reach 80,470 by the end of 2019 in the country. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, in 2016, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the centre for drug research and development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology.

The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

Major players in the market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb
Note: Product cover images may vary from those shown
5 of 5
  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Sanofi
  • Hoffmann-La Roche
  • Novartis International
  • Johnson & Johnson
  • Merck & Co Inc
  • Vault Pharma Inc
  • Vyriad Inc
  • Boehringer Ingelheim GmbH
  • Bayer AG
  • Asieris Pharmaceuticals Co Ltd
  • Asana BioSciences LLC
  • Array BioPharma Inc
  • Archivel Farma SL
  • AndroScience Corp
  • Amgen Inc
  • Altor BioScience Corp
  • Alligator Bioscience AB
  • Adaptimmune Therapeutics Plc
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll